Jim Lagopoulos
Research Subjects
Jim Lagopoulos has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Francis Hermens
Thompson Institute University of the Sunshine Coast Sunshine Coast Queensland Australia
5 shared publications - Adem Tevfik Can
National PTSD Research Centre, Thompson Institute, University of the Sunshine Coast (UniSC), Birtinya, QLD, Australia
4 shared publications - Anna Kuballa
School of Health, UniSC, Sippy Downs, QLD, Australia; Centre for Bioinnovation, UniSC, Sippy Downs, QLD, Australia; Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service, Birtinya, QLD, 4575, Australia
4 shared publications Megan Dutton
Thompson Brain and Mind Healthcare
4 shared publications- Nathan J. Wellington
National PTSD Research Centre, Thompson Institute, University of the Sunshine Coast (UniSC)
4 shared publications Adem T. Can
Univ Sunshine Coast, Thompson Inst, Birtinya, Qld, Australia
3 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 60 (2) , 110-114
Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy
Ketamine has emerged as a rapid-acting intervention for treatment-resistant psychiatric disorders, generating both enthusiasm and unease. While evidence demonstrates robust antidepressant, anxiolytic and anti-suicidal effects, ketamine also carries risks, including dissociation, dependence and uncertain long-term safety. Its reputation as a recreational drug further complicates clinical adoption, fostering stigma and regulatory caution. In this article, we consider ketamine’s psychiatric use through the lens of medical ethics, structured around the principles of autonomy, beneficence, non-maleficence and justice. We argue that while ketamine should be embraced as a legitimate psychiatric therapy, its application must be grounded in rigorous ethical practice, supported by regulation and research, and shielded from both undue dismissal and premature over-promotion.
- 11 December 2025
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 60 (2) , 110-114
Open AccessKetamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy
Ketamine has emerged as a rapid-acting intervention for treatment-resistant psychiatric disorders, generating both enthusiasm and unease. While evidence demonstrates robust antidepressant, anxiolytic and anti-suicidal effects, ketamine also carries risks, including dissociation, dependence and uncertain long-term safety. Its reputation as a recreational drug further complicates clinical adoption, fostering stigma and regulatory caution. In this article, we consider ketamine’s psychiatric use through the lens of medical ethics, structured around the principles of autonomy, beneficence, non-maleficence and justice. We argue that while ketamine should be embraced as a legitimate psychiatric therapy, its application must be grounded in rigorous ethical practice, supported by regulation and research, and shielded from both undue dismissal and premature over-promotion.
- Open Access
- 30 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 395 (Pt B) , 120791
Temporal immune effects of Oral ketamine on PTSD: Transcriptomic evidence of short-term inflammation suppression and sustained immune Remodelling
- 30 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 395 (Pt B) , 120791
Open AccessTemporal immune effects of Oral ketamine on PTSD: Transcriptomic evidence of short-term inflammation suppression and sustained immune Remodelling
- Open Access
- 25 August 2025
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 4 (2)
Complete resolution of urge urinary incontinence following treatment of ADHD with lisdexamfetamine: a case report
- 25 August 2025
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 4 (2)
Open AccessComplete resolution of urge urinary incontinence following treatment of ADHD with lisdexamfetamine: a case report
- Open Access
Methylome and transcriptome functional analysis identifies key biomarkers in ketamine’s sustained therapeutic effect on PTSD
Background Ketamine has emerged as a rapid-acting therapeutic option for post-traumatic stress disorder (PTSD); however, its ability to sustain long-term therapeutic outcomes remains poorly understood. Identifying molecular biomarkers predictive of a sustained response to ketamine may enhance personalised treatment strategies. This study investigates the epigenetic and transcriptomic precursors underpinning ketamine’s long-term therapeutic efficacy in PTSD. Methods This study utilised data from the Oral Ketamine Trial of PTSD (OKTOP), an open-label, dose-ranging clinical study conducted between 2021 and 2024. Baseline differential DNA methylation and gene expression profiles of sustained responders (clinical response >1 month post-ketamine treatment) were compared against non-responders. Epigenomic and transcriptomic analyses were performed to identify differentially regulated genes associated with ketamine response. Results Baseline molecular analyses revealed significant differential methylation and transcriptomic profiles across 112 genes. Key biomarkers included DENND5B (cg02046589), ZFY (cg00272582), PDGFRA (cg21309167), CPT1A (cg10098373), AHRR (cg26076054), RPH3AL (cg17316718), CHI3L1 (cg19081101), UTY (cg04790916), LDHD (cg00004883), TBC1D16 (cg26287152), FAM66A (cg23285059), NME8 (cg02531859), EIF1AY (cg13308744), PCBP3 (cg13695288), PAQR6 (cg03954786), KCNK17 (cg19475903), PLPP2 (cg24452451), ANK1 (cg23668222), LINC00200 (C10ORF139, cg19282259), ALAS2 (cg07471703), ZBP1 (cg06305758), TACSTD2 (cg01821018), and PLEKHH3 (cg24455236). These biomarkers were implicated in pathways related to metabolism, transcriptional regulation, cell signalling, neuronal development, immune response, synaptic plasticity, and cytoskeletal organisation. Non-responders exhibited persistent dysregulation across these pathways, suggesting potential biological barriers to treatment efficacy. Clinically, sustained responders presented with higher baseline PTSD severity and demonstrated a response at lower ketamine doses compared to non-responders. Conclusions This study highlights the potential of methylomic and transcriptomic profiling to identify functional biomarkers predictive of ketamine response in PTSD. The observed molecular distinctions between responders and non-responders suggest a complex interplay between clinical presentation and treatment outcomes. These findings contribute to advancing precision medicine approaches for PTSD by informing biomarker-driven treatment stratification and optimisation of ketamine therapy.
Open AccessMethylome and transcriptome functional analysis identifies key biomarkers in ketamine’s sustained therapeutic effect on PTSD
Background Ketamine has emerged as a rapid-acting therapeutic option for post-traumatic stress disorder (PTSD); however, its ability to sustain long-term therapeutic outcomes remains poorly understood. Identifying molecular biomarkers predictive of a sustained response to ketamine may enhance personalised treatment strategies. This study investigates the epigenetic and transcriptomic precursors underpinning ketamine’s long-term therapeutic efficacy in PTSD. Methods This study utilised data from the Oral Ketamine Trial of PTSD (OKTOP), an open-label, dose-ranging clinical study conducted between 2021 and 2024. Baseline differential DNA methylation and gene expression profiles of sustained responders (clinical response >1 month post-ketamine treatment) were compared against non-responders. Epigenomic and transcriptomic analyses were performed to identify differentially regulated genes associated with ketamine response. Results Baseline molecular analyses revealed significant differential methylation and transcriptomic profiles across 112 genes. Key biomarkers included DENND5B (cg02046589), ZFY (cg00272582), PDGFRA (cg21309167), CPT1A (cg10098373), AHRR (cg26076054), RPH3AL (cg17316718), CHI3L1 (cg19081101), UTY (cg04790916), LDHD (cg00004883), TBC1D16 (cg26287152), FAM66A (cg23285059), NME8 (cg02531859), EIF1AY (cg13308744), PCBP3 (cg13695288), PAQR6 (cg03954786), KCNK17 (cg19475903), PLPP2 (cg24452451), ANK1 (cg23668222), LINC00200 (C10ORF139, cg19282259), ALAS2 (cg07471703), ZBP1 (cg06305758), TACSTD2 (cg01821018), and PLEKHH3 (cg24455236). These biomarkers were implicated in pathways related to metabolism, transcriptional regulation, cell signalling, neuronal development, immune response, synaptic plasticity, and cytoskeletal organisation. Non-responders exhibited persistent dysregulation across these pathways, suggesting potential biological barriers to treatment efficacy. Clinically, sustained responders presented with higher baseline PTSD severity and demonstrated a response at lower ketamine doses compared to non-responders. Conclusions This study highlights the potential of methylomic and transcriptomic profiling to identify functional biomarkers predictive of ketamine response in PTSD. The observed molecular distinctions between responders and non-responders suggest a complex interplay between clinical presentation and treatment outcomes. These findings contribute to advancing precision medicine approaches for PTSD by informing biomarker-driven treatment stratification and optimisation of ketamine therapy.
- Open Access
Temporal Immune Effects of Oral Ketamine on PTSD: Transcriptomic Evidence of Short-Term Inflammation Suppression and Long-Term Immune Remodelling
Ketamine’s rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs) were collected at baseline, one week (short-term), and four weeks (long-term) post oral ketamine for RNA sequencing and transcriptome analysis. Differential expression analysis identified substantial and persistent transcriptomic changes over time, with 533 genes upregulated and 621 downregulated across timepoints. Notably, there was a 37% increase in differential gene expression between the short-and long-term responses, accompanied by a 6.5-fold rise in expression magnitude and an 8.8-fold enhancement in pathway activity. Pathway analysis emphasised critical immune and inflammatory pathways that appear to be modulated by ketamine, including interferon alpha/beta signalling ( z = 4), IL-17 signalling pathway ( z = 3.36), and cytokine storm signalling ( z = 4.26), neutrophil degranulation (z = 6.0) and antimicrobial peptide signalling ( z = 1.63) which differed across timepoints. The findings suggest a transition from short-term inflammation suppression and antimicrobial activity to long-term sustained immune regulation, inflammation remodulation and tissue repair. Key cytokines, chemokines, interferons and antimicrobial peptides included, IL-6, IL-1β, IFI27, IL-10 signalling, CXCL8, SOCS1/3 and CAMP which represent central regulators of immune and inflammatory pathways. These molecular changes offer novel insights into the short-and long-term therapeutic potential of ketamine for PTSD and highlight avenues for precision psychiatry and individualised maintenance therapy to prevent relapse.
Open AccessTemporal Immune Effects of Oral Ketamine on PTSD: Transcriptomic Evidence of Short-Term Inflammation Suppression and Long-Term Immune Remodelling
Ketamine’s rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs) were collected at baseline, one week (short-term), and four weeks (long-term) post oral ketamine for RNA sequencing and transcriptome analysis. Differential expression analysis identified substantial and persistent transcriptomic changes over time, with 533 genes upregulated and 621 downregulated across timepoints. Notably, there was a 37% increase in differential gene expression between the short-and long-term responses, accompanied by a 6.5-fold rise in expression magnitude and an 8.8-fold enhancement in pathway activity. Pathway analysis emphasised critical immune and inflammatory pathways that appear to be modulated by ketamine, including interferon alpha/beta signalling ( z = 4), IL-17 signalling pathway ( z = 3.36), and cytokine storm signalling ( z = 4.26), neutrophil degranulation (z = 6.0) and antimicrobial peptide signalling ( z = 1.63) which differed across timepoints. The findings suggest a transition from short-term inflammation suppression and antimicrobial activity to long-term sustained immune regulation, inflammation remodulation and tissue repair. Key cytokines, chemokines, interferons and antimicrobial peptides included, IL-6, IL-1β, IFI27, IL-10 signalling, CXCL8, SOCS1/3 and CAMP which represent central regulators of immune and inflammatory pathways. These molecular changes offer novel insights into the short-and long-term therapeutic potential of ketamine for PTSD and highlight avenues for precision psychiatry and individualised maintenance therapy to prevent relapse.
- Open Access
- 2 July 2024
- Published by Taylor & Francis in Journal of Neurogenetics
- Vol. 38 (3) , 79-101
Clinical potential of epigenetic and microRNA biomarkers in PTSD
Molecular studies identifying alterations associated with PTSD have predominantly focused on candidate genes or conducted genome-wide analyses, often encountering issues with replicability. This review aims to identify robust bi-directional epigenetic and microRNA (miRNA) regulators focusing on their functional impacts on post-traumatic stress disorder (PTSD) and their utility in clinical diagnosis, whilst examining knowledge gaps in the existing research. A systematic search was conducted across multiple databases, including Web of Science, Scopus, Global Health (CABI), and PubMed, augmented by grey literature, yielding 3465 potential articles. Ultimately, 92 studies met the inclusion criteria and were analysed to pinpoint significant epigenetic changes with clinically relevant potential in PTSD. The selected studies explored histone modifications, CpG sites, single nucleotide polymorphisms (SNPs), and miRNA biomarkers. Specifically, nine studies examined epigenetic markers, detailing the influence of methylation on chromatin accessibility at histone positions H3K4, H3K9, and H3K36 within a PTSD context. Seventy-three studies investigated DNA methylation, identifying 20 hypermethylated and five hypomethylated CpG islands consistently observed in PTSD participants. Nineteen studies linked 88 SNPs to PTSD, with only one SNP replicated within these studies. Furthermore, sixteen studies focused on miRNAs, with findings indicating 194 downregulated and 24 upregulated miRNAs were associated with PTSD. Although there are epigenetic mechanisms that are significantly affected by PTSD, a granular deconstruction of these mechanisms elucidates the need to incorporate more nuanced approaches to identifying the factors that contribute to PTSD. Technological advances in diagnostic tools are driving the need to integrate detailed participant characteristics, trauma type, genetic susceptibilities, and best practices for robust reporting. This comprehensive approach will be crucial for enhancing the translational potential of PTSD research for clinical application.
- 2 July 2024
- Published by Taylor & Francis in Journal of Neurogenetics
- Vol. 38 (3) , 79-101
Open AccessClinical potential of epigenetic and microRNA biomarkers in PTSD
Molecular studies identifying alterations associated with PTSD have predominantly focused on candidate genes or conducted genome-wide analyses, often encountering issues with replicability. This review aims to identify robust bi-directional epigenetic and microRNA (miRNA) regulators focusing on their functional impacts on post-traumatic stress disorder (PTSD) and their utility in clinical diagnosis, whilst examining knowledge gaps in the existing research. A systematic search was conducted across multiple databases, including Web of Science, Scopus, Global Health (CABI), and PubMed, augmented by grey literature, yielding 3465 potential articles. Ultimately, 92 studies met the inclusion criteria and were analysed to pinpoint significant epigenetic changes with clinically relevant potential in PTSD. The selected studies explored histone modifications, CpG sites, single nucleotide polymorphisms (SNPs), and miRNA biomarkers. Specifically, nine studies examined epigenetic markers, detailing the influence of methylation on chromatin accessibility at histone positions H3K4, H3K9, and H3K36 within a PTSD context. Seventy-three studies investigated DNA methylation, identifying 20 hypermethylated and five hypomethylated CpG islands consistently observed in PTSD participants. Nineteen studies linked 88 SNPs to PTSD, with only one SNP replicated within these studies. Furthermore, sixteen studies focused on miRNAs, with findings indicating 194 downregulated and 24 upregulated miRNAs were associated with PTSD. Although there are epigenetic mechanisms that are significantly affected by PTSD, a granular deconstruction of these mechanisms elucidates the need to incorporate more nuanced approaches to identifying the factors that contribute to PTSD. Technological advances in diagnostic tools are driving the need to integrate detailed participant characteristics, trauma type, genetic susceptibilities, and best practices for robust reporting. This comprehensive approach will be crucial for enhancing the translational potential of PTSD research for clinical application.
- Open Access
- 22 April 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 59 (12) , 3322-3336
Chronotype and subjective sleep quality predict white matter integrity in young people with emerging mental disorders
Protecting brain health is a goal of early intervention. We explored whether sleep quality or chronotype could predict white matter (WM) integrity in emerging mental disorders. Young people (N = 364) accessing early‐intervention clinics underwent assessments for chronotype, subjective sleep quality, and diffusion tensor imaging. Using machine learning, we examined whether chronotype or sleep quality (alongside diagnostic and demographic factors) could predict four measures of WM integrity: fractional anisotropy (FA), and radial, axial, and mean diffusivities (RD, AD and MD). We prioritised tracts that showed a univariate association with sleep quality or chronotype and considered predictors identified by ≥80% of machine learning (ML) models as ‘important’. The most important predictors of WM integrity were demographics (age, sex and education) and diagnosis (depressive and bipolar disorders). Subjective sleep quality only predicted FA in the perihippocampal cingulum tract, whereas chronotype had limited predictive importance for WM integrity. To further examine links with mood disorders, we conducted a subgroup analysis. In youth with depressive and bipolar disorders, chronotype emerged as an important (often top‐ranking) feature, predicting FA in the cingulum (cingulate gyrus), AD in the anterior corona radiata and genu of the corpus callosum, and RD in the corona radiata, anterior corona radiata, and genu of corpus callosum. Subjective quality was not important in this subgroup analysis. In summary, chronotype predicted altered WM integrity in the corona radiata and corpus callosum, whereas subjective sleep quality had a less significant role, suggesting that circadian factors may play a more prominent role in WM integrity in emerging mood disorders.
- 22 April 2024
- Published by Wiley in European Journal of Neuroscience
- Vol. 59 (12) , 3322-3336
Open AccessChronotype and subjective sleep quality predict white matter integrity in young people with emerging mental disorders
Protecting brain health is a goal of early intervention. We explored whether sleep quality or chronotype could predict white matter (WM) integrity in emerging mental disorders. Young people (N = 364) accessing early‐intervention clinics underwent assessments for chronotype, subjective sleep quality, and diffusion tensor imaging. Using machine learning, we examined whether chronotype or sleep quality (alongside diagnostic and demographic factors) could predict four measures of WM integrity: fractional anisotropy (FA), and radial, axial, and mean diffusivities (RD, AD and MD). We prioritised tracts that showed a univariate association with sleep quality or chronotype and considered predictors identified by ≥80% of machine learning (ML) models as ‘important’. The most important predictors of WM integrity were demographics (age, sex and education) and diagnosis (depressive and bipolar disorders). Subjective sleep quality only predicted FA in the perihippocampal cingulum tract, whereas chronotype had limited predictive importance for WM integrity. To further examine links with mood disorders, we conducted a subgroup analysis. In youth with depressive and bipolar disorders, chronotype emerged as an important (often top‐ranking) feature, predicting FA in the cingulum (cingulate gyrus), AD in the anterior corona radiata and genu of the corpus callosum, and RD in the corona radiata, anterior corona radiata, and genu of corpus callosum. Subjective quality was not important in this subgroup analysis. In summary, chronotype predicted altered WM integrity in the corona radiata and corpus callosum, whereas subjective sleep quality had a less significant role, suggesting that circadian factors may play a more prominent role in WM integrity in emerging mood disorders.
- 5 July 2023
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 77 (10) , 513-529
Insights into the neurobiology of suicidality: explicating the role of glutamatergic systems through the lens of ketamine
Suicidality is a prevalent mental health condition, and managing suicidal patients is one of the most challenging tasks for health care professionals due to the lack of rapid‐acting, effective psychopharmacological treatment options. According to the literature, suicide has neurobiological underpinnings that are not fully understood, and current treatments for suicidal tendencies have considerable limitations. To treat suicidality and prevent suicide, new treatments are required; to achieve this, the neurobiological processes underlying suicidal behavior must be thoroughly investigated. Although multiple neurotransmitter systems, particularly serotonergic systems, have been studied in the past, less has been reported in relation to disruptions in glutamatergic neurotransmission, neuronal plasticity, and neurogenesis that result from stress‐related abnormalities of the hypothalamic–pituitary–adrenal system. Informed by the literature, which reports robust antisuicidal and antidepressive properties of subanaesthetic doses of ketamine, this review aims to provide an examination of the neurobiology of suicidality (and relevant mood disorders) with implications of pertinent animal, clinical, and postmortem studies. We discuss dysfunctions in the glutamatergic system, which may play a role in the neuropathology of suicidality and the role of ketamine in restoring synaptic connectivity at the molecular levels.
- 5 July 2023
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 77 (10) , 513-529
Insights into the neurobiology of suicidality: explicating the role of glutamatergic systems through the lens of ketamine
Suicidality is a prevalent mental health condition, and managing suicidal patients is one of the most challenging tasks for health care professionals due to the lack of rapid‐acting, effective psychopharmacological treatment options. According to the literature, suicide has neurobiological underpinnings that are not fully understood, and current treatments for suicidal tendencies have considerable limitations. To treat suicidality and prevent suicide, new treatments are required; to achieve this, the neurobiological processes underlying suicidal behavior must be thoroughly investigated. Although multiple neurotransmitter systems, particularly serotonergic systems, have been studied in the past, less has been reported in relation to disruptions in glutamatergic neurotransmission, neuronal plasticity, and neurogenesis that result from stress‐related abnormalities of the hypothalamic–pituitary–adrenal system. Informed by the literature, which reports robust antisuicidal and antidepressive properties of subanaesthetic doses of ketamine, this review aims to provide an examination of the neurobiology of suicidality (and relevant mood disorders) with implications of pertinent animal, clinical, and postmortem studies. We discuss dysfunctions in the glutamatergic system, which may play a role in the neuropathology of suicidality and the role of ketamine in restoring synaptic connectivity at the molecular levels.
- Open Access
- 22 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (5) , 872
Precision Medicine for Brain Disorders: New and Emerging Approaches
The brain is the most complex organ in the human body, making it susceptible to many abnormalities
- 22 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (5) , 872
Open AccessPrecision Medicine for Brain Disorders: New and Emerging Approaches
The brain is the most complex organ in the human body, making it susceptible to many abnormalities
- 22 March 2023
- Published by Elsevier in Journal of Affective Disorders
- Vol. 331, 92-100
Treatment response with ketamine in chronic suicidality: An open label functional connectivity study
- 22 March 2023
- Published by Elsevier in Journal of Affective Disorders
- Vol. 331, 92-100
Treatment response with ketamine in chronic suicidality: An open label functional connectivity study